The Macrophage Stimulating Protein Receptor pipeline drugs market research report outlays comprehensive information on the Macrophage Stimulating Protein Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Macrophage Stimulating Protein Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Genetic Disorders which include the indications Breast Cancer, Pancreatic Cancer, and Neurofibromatoses Type I (Von Recklinghausen’s Disease). It also reviews key players involved in Macrophage Stimulating Protein Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Macrophage Stimulating Protein Receptor pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 1, 3, and 1 respectively.
Macrophage Stimulating Protein Receptor overview
Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.
For a complete picture of Macrophage Stimulating Protein Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
